SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Imunon, Inc.
Date: June 5, 2025 · CIK: 0000749647 · Accession: 0000000000-25-005918

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-287699

Date
June 5, 2025
Author
Division of
Form
UPLOAD
Company
Imunon, Inc.

Letter

Re: Imunon, Inc. Registration Statement on Form S-1 File No. 333-287699 Filed May 30, 2025 Dear Stacy Lindborg:

June 5, 2025

Stacy Lindborg President and Chief Executive Officer Imunon, Inc. 997 Lenox Drive, Suite 100 Lawrenceville, NJ 08648

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jurgita Ashley

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 June 5, 2025

Stacy Lindborg
President and Chief Executive Officer
Imunon, Inc.
997 Lenox Drive, Suite 100
Lawrenceville, NJ 08648

 Re: Imunon, Inc.
 Registration Statement on Form S-1
 File No. 333-287699
 Filed May 30, 2025
Dear Stacy Lindborg:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jurgita Ashley
</TEXT>
</DOCUMENT>